David Pauling Purchases 12,504 Shares of Sutro Biopharma (NASDAQ:STRO) Stock

Sutro Biopharma, Inc. (NASDAQ:STRO - Get Free Report) insider David Pauling acquired 12,504 shares of Sutro Biopharma stock in a transaction on Wednesday, October 15th. The shares were purchased at an average price of $0.80 per share, with a total value of $10,003.20. Following the completion of the purchase, the insider owned 71,737 shares in the company, valued at $57,389.60. This represents a 21.11% increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.

Sutro Biopharma Stock Performance

Shares of NASDAQ STRO opened at $0.88 on Friday. The firm's 50 day moving average price is $0.88 and its 200-day moving average price is $0.83. Sutro Biopharma, Inc. has a 52-week low of $0.52 and a 52-week high of $4.60. The company has a market cap of $74.66 million, a PE ratio of -0.35 and a beta of 1.61.

Sutro Biopharma (NASDAQ:STRO - Get Free Report) last posted its quarterly earnings results on Thursday, August 7th. The company reported ($0.14) EPS for the quarter, beating analysts' consensus estimates of ($0.39) by $0.25. Sutro Biopharma had a negative net margin of 201.32% and a negative return on equity of 852.70%. The firm had revenue of $63.74 million for the quarter, compared to analysts' expectations of $14.55 million. On average, analysts forecast that Sutro Biopharma, Inc. will post -2.92 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of equities research analysts have recently commented on the stock. Wells Fargo & Company cut their price target on shares of Sutro Biopharma from $4.00 to $3.00 and set an "equal weight" rating on the stock in a report on Tuesday, August 12th. Weiss Ratings reiterated a "sell (e+)" rating on shares of Sutro Biopharma in a report on Wednesday, October 8th. Finally, Wall Street Zen upgraded shares of Sutro Biopharma from a "sell" rating to a "hold" rating in a report on Saturday, September 13th. Two research analysts have rated the stock with a Buy rating, four have given a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat, Sutro Biopharma has an average rating of "Hold" and an average target price of $4.47.

Read Our Latest Stock Report on STRO

Institutional Trading of Sutro Biopharma

Institutional investors have recently made changes to their positions in the stock. Catalyst Funds Management Pty Ltd purchased a new stake in shares of Sutro Biopharma during the 2nd quarter valued at about $27,000. Cerity Partners LLC purchased a new stake in shares of Sutro Biopharma during the 1st quarter valued at about $25,000. Vontobel Holding Ltd. boosted its holdings in shares of Sutro Biopharma by 100.0% during the 1st quarter. Vontobel Holding Ltd. now owns 50,000 shares of the company's stock valued at $33,000 after acquiring an additional 25,000 shares during the last quarter. Savant Capital LLC purchased a new stake in shares of Sutro Biopharma during the 2nd quarter valued at about $37,000. Finally, CWM LLC boosted its holdings in shares of Sutro Biopharma by 73.2% during the 2nd quarter. CWM LLC now owns 56,657 shares of the company's stock valued at $40,000 after acquiring an additional 23,941 shares during the last quarter. Hedge funds and other institutional investors own 96.99% of the company's stock.

Sutro Biopharma Company Profile

(Get Free Report)

Sutro Biopharma, Inc operates as a clinical-stage oncology company. The company develops site-specific and novel-format antibody drug conjugates (ADCs) that enables its proprietary integrated cell-free protein synthesis platform, XpressCF and XpressCF+. Its product candidates include STRO-002, an ADC directed against folate receptor-alpha, which is in Phase II/III clinical trials for patients with ovarian and endometrial cancers; VAX-24 and Vax-31 pneumococcal conjugate vaccine candidates that is in Phase II/III clinical trials for the treatment of invasive pneumococcal disease; and MK-1484, a distinct cytokine derivative molecule that is in Phase I clinical study for the treatment of cancer.

Featured Articles

• Five stocks we like better than Sutro Biopharma
• How Technical Indicators Can Help You Find Oversold Stocks
• Salesforce’s Long-Awaited Inflection is Here: Rally On!
• Trading Halts Explained
• Rocket Lab USA Receives Wall Street Validation: Time to Buy?
• What is Short Interest? How to Use It
• Archer Buys Rival's Patent Treasure Trove in Strategic Move

This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].